Aktis Oncology Inc

Research Aktis Oncology Inc (AKTS) on Bullrun: market cap USD 1.66B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAKTS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.66B
• Financial periodQ1 2026
• RevenueUSD 3.23M
• Net income-USD 18.33M
• Free cash flow-USD 26.10M

Valuation Snapshot

latest market cap is USD 1.66B.

About Aktis Oncology Inc

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer;

Frequently asked questions

What is Aktis Oncology Inc's market cap?

Aktis Oncology Inc's market capitalization is USD 1.66B.

What does Aktis Oncology Inc do?

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.